Sally Blower, Katia Koelle, and John Mills
- Published in print:
- 2001
- Published Online:
- October 2013
- ISBN:
- 9780300087512
- eISBN:
- 9780300128222
- Item type:
- chapter
- Publisher:
- Yale University Press
- DOI:
- 10.12987/yale/9780300087512.003.0014
- Subject:
- Sociology, Health, Illness, and Medicine
This chapter discusses the obstacles to HIV vaccine development and reviews vaccine strategies currently under development. It discusses HIV epidemic control models as health policy tools. These ...
More
This chapter discusses the obstacles to HIV vaccine development and reviews vaccine strategies currently under development. It discusses HIV epidemic control models as health policy tools. These models can be used to design vaccination strategies to eliminate HIV and to assess the epidemiological impact of behavioral changes that occur with a mass vaccination campaign against HIV.Less
This chapter discusses the obstacles to HIV vaccine development and reviews vaccine strategies currently under development. It discusses HIV epidemic control models as health policy tools. These models can be used to design vaccination strategies to eliminate HIV and to assess the epidemiological impact of behavioral changes that occur with a mass vaccination campaign against HIV.
Owen Barder, Michael Kremer, and Heidi Williams
- Published in print:
- 2011
- Published Online:
- November 2015
- ISBN:
- 9780231143653
- eISBN:
- 9780231527866
- Item type:
- chapter
- Publisher:
- Columbia University Press
- DOI:
- 10.7312/columbia/9780231143653.003.0007
- Subject:
- Economics and Finance, Public and Welfare
Vaccines arguably offer the best hope for tackling diseases such as malaria, tuberculosis, and HIV that are concentrated in poor countries. However, there is a dearth of research and development on ...
More
Vaccines arguably offer the best hope for tackling diseases such as malaria, tuberculosis, and HIV that are concentrated in poor countries. However, there is a dearth of research and development on such vaccines. This chapter outlines the economic rationale for the “Advance Market Commitment” proposal, which the G8 finance ministers decided to pilot in 2006. Under the proposal, donors commit to help finance the purchase of vaccines against neglected diseases, if and when such vaccines are developed. The chapter first summarizes the value of vaccines in addressing diseases in poor countries. It then outlines two market failures that limit private sector investment in vaccines against neglected diseases. It argues that advance market commitments could accelerate the development of new vaccines for neglected diseases by addressing each of these market failures, and describes how such commitments can be designed to facilitate widespread access to these vaccines if they are developed. Finally, it discusses evidence suggesting that advance market commitments would be a cost-effective way for donors to save more lives than would be saved by virtually any comparable health expenditure.Less
Vaccines arguably offer the best hope for tackling diseases such as malaria, tuberculosis, and HIV that are concentrated in poor countries. However, there is a dearth of research and development on such vaccines. This chapter outlines the economic rationale for the “Advance Market Commitment” proposal, which the G8 finance ministers decided to pilot in 2006. Under the proposal, donors commit to help finance the purchase of vaccines against neglected diseases, if and when such vaccines are developed. The chapter first summarizes the value of vaccines in addressing diseases in poor countries. It then outlines two market failures that limit private sector investment in vaccines against neglected diseases. It argues that advance market commitments could accelerate the development of new vaccines for neglected diseases by addressing each of these market failures, and describes how such commitments can be designed to facilitate widespread access to these vaccines if they are developed. Finally, it discusses evidence suggesting that advance market commitments would be a cost-effective way for donors to save more lives than would be saved by virtually any comparable health expenditure.
